Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this month.
Dr. Robert A. Winn discusses efforts to increase diversity in clinical trials on an episode of Radio Health Journal.
2hon MSN
Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subc ...
Researchers have applied AI to every step of the drug development process. But this might not be enough to design safe and ...
Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...
Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...
In 2023, drug companies launched new medications at prices 35 percent higher than the year before. On January 1, Pfizer ...
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was the target of unusually large options trading activity on Thursday. Stock investors acquired 296,826 call options on the company. This is an ...
Drugmakers plan to raise US prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol ...
Non-transplant salvage therapy for low-risk relapsed/refractory pediatric classical Hodgkin lymphoma (cHL) had high rates of ...
This was the stock's second consecutive day of gains.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback